Erratum: Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo (PLoS One (2013) 8:1 (e52940) DOI: 10.1371/journal.pone.0052940);Synthesized Multiple Antigenic Polypeptide Vaccine Based on B-Cell Epitopes of Human Heparanase Could Elicit a Potent Antimetastatic Effect on Human Hepatocellular Carcinoma In Vivo

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zhang, Jun ^a,b   Yang, Jian min ^b   Wang, Hui ju ^c   Ru, Guo qing ^b   Fan, Dai ming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Key Laboratory of Gastroenterology of Zhejiang Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FIBROBLAST GROWTH FACTOR 2; HEPARANASE; MULTIPLE ANTIGENIC POLYPEPTIDE POLYCLONAL ANTIBODY; MULTIPLE ANTIGENIC POLYPEPTIDE VACCINE; PEPTIDE VACCINE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MEGADOSE; DRUG POTENCY; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; MALE; METASTASIS; METASTASIS INHIBITION; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RABBIT;

MURINAE; MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

EID: 84872023276     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0226124     Document Type: Erratum

References (37)

1. Schutte K, Bornschein J, Malfertheiner P, (2009) Hepatocellular carcinoma -epidemiological trends and risk factors. Dig Dis 27: 80-92.
2. Llovet JM, Bruix J, (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
3. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
4. Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, et al. (2011) Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117: 4475-4483.
5. Fidler IJ, Ellis LM, (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188.
6. Ferrara N, (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280: 1358-1366.
7. Kaikai S, Yuchen S, Lili J, Zhengtao W, (2011) Critical role of c-Jun N-terminal kinase in regulating bFGF-induced angiogenesis in vitro. J Biochem 150: 189-197.
8. Weidner N, (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19.
9. Sawai H, Okada Y, Funahashi H, Takahashi H, Matsuo Y, et al. (2008) Basement membrane proteins play an important role in the invasive processes of human pancreatic cancer cells. J Surg Res 144: 117-123.
10. Vlodavsky I, Ilan N, Naggi A, Casu B, (2007) Heparanase: structure, biologica functions, and inhibition by heparin-derived mimetics of heparin sulfate. Curr Pharm Des 13: 2057-2073.
11. Roy M, Marchetti D, (2009) Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem 106: 200-209.
12. Nasser NJ, Avivi A, Shafat I, Edovitsky E, Zcharia E, et al. (2009) Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis. Proc Natl Acad Sci USA 106: 2253-2258.
13. Zhao H, Liu H, Chen Y, Xin X, Li J, et al. (2006) Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basicWbroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res 66: 8779-8787.
14. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z, (2006) Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13: 2101-2111.
15. Vlodavsky I, Elkin M, Abboud JG, Levi-Adam F, Fuks L, et al. (2008) Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 49: 207-210.
16. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, et al. (2007) PI-88 and novel heparin sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 33: 557-568.
17. Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, et al. (2002) Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 12: 121-129.
18. Yang JM, Wang HJ, Du L, Han XM, Ye ZY, et al. (2009) Screening and identification of novel B cell epitopes in human heparanase and their anti-invasion property for hepatocellular carcinoma. Cancer Immunol Immunother 58: 1387-1396.
19. Du L, Wang HJ, Yang JM, (2008) T-helper epitope peptide improves immunological effects of the B cell epitopes of human heparanase protein. Chin J Microbiol Immunol 28: 869-872.
20. Liu XB, Cai MY, Wang X, Li XR, (1999) One Simple and Efficient Method for Purification of IgG Ab from Mice Ascites and Sera: Caprylic Acid/Ammonium Sulfate Precipitation. J WCUMS 30: 455-456.
21. Han XM, Wang HJ, Yang JM, (2009) Effects of anti-heparanase antibody on the growth and invasion of HCCLM6 human hepatocellular carcinoma cells. Chin J Oncology 31: 10-14.
22. Hao XS, Wang PP, Chen KX, Li Q, He M, et al. (2003) Twenty-year trends of primary liver cancer incidence rate in an urban Chinese population. Eur J Can Prev 12: 273-279.
23. McKenzie EA, (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151: 1-14.
24. Ilan N, Elkin M, Vlodavsky I, (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 12: 2018-2039.
25. Zarour HM, Ferrone S, (2011) Cancer immunotherapy: Progress and challenges in the clinical setting. Eur J Immunol 41: 1510-1516.
26. Sommerfeldt N, Beckhove P, Ge Y, Schütz F, Choi C, et al. (2006) Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 66: 7716-7723.
27. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, et al. (1999) New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81: 814-21.
28. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, et al. (2004) A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 187-196.
29. Li Y, Tang ZY, Ye SL, (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 5: 630-636.
30. Shen FG, (2011) Research Progress in Animal Models of Liver Cancer. Journal of Anhui Agri Sci 20: 12264-12266.
31. Katz M, Lynn M, Solotorovsky M, (1981) Serological and Biological Activities of Anti-Haemophilus influenzae Ribosomal Serum. Infect Immun 31: 1125-1131.
32. Chan A, (2007) A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 18: 1152-1158.
33. Levy-Adam F, Abboud-Jarrous G, Guerrini M, (2005) Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 21: 20457-20466.
34. An FQ, Matsuda M, Fujii H, Matsumoto Y, (2000) Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol 126: 153-160.
35. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, et al. (2011) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233: 227-235.
36. Xu YZ, Zhu Y, Shen ZJ, Sheng JY, He HC, et al. (2011) Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine 40: 445-451.
37. Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I, Ilan N, (2008) Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One 6: e2319.